等级
pharmaceutical primary standard
API类
oxcarbazepine
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
格式
neat
SMILES字符串
O=C1CC2=C(C=CC=C2)N(C(N)=O)C3=CC=CC=C31
InChI
1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
InChI key
CTRLABGOLIVAIY-UHFFFAOYSA-N
基因信息
human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Oxcarbazepine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Oxcarbazepine Oral Suspension
- Oxcarbazepine Tablets
生化/生理作用
抗惊厥药，止痛药。抑制藜芦碱诱导的递质释放。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
A Vasudev et al.
The Cochrane database of systematic reviews, (1)(1), CD005171-CD005171 (2008-02-07)
Some studies have suggested that oxcarbazepine has a role in preventing episode recurrence in bipolar affective disorder. This review attempted to investigate the existing evidence from randomised controlled trials for its use in the maintenance treatment of this illness. To
Barbara R Sommer et al.
Expert opinion on drug safety, 6(2), 133-145 (2007-03-21)
Few controlled studies are available to guide the clinician in treating potentially assaultive elderly individuals with psychiatric disorders. Safety concerns limit the use of benzodiazepines and antipsychotic medications in the elderly individual, making anticonvulsants an attractive alternative. This paper reviews
Gaetano Zaccara et al.
Seizure, 22(7), 528-536 (2013-04-30)
Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three
Wetid Pratoomsri et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 51(8), 540-545 (2006-08-29)
To review the data on the efficacy of oxcarbazepine (OXC) in bipolar disorder (BD) and to provide recommendations for clinicians on the use of this medication in treating BD. Using the terms oxcarbazepine and bipolar disorder, oxcarbazepine and mania, or
Penny Bring et al.
Clinical pharmacokinetics, 47(12), 767-778 (2008-11-26)
Oxcarbazepine, the 10-keto analogue of carbamazepine, is approved for the treatment of partial seizures or generalized tonic-clonic seizures. The primary metabolite of oxcarbazepine is monohydroxylated derivative (MHD). This review follows a decision-making algorithm to determine if therapeutic drug monitoring of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门